Glaukos Co. (NYSE:GKOS) Receives $147.75 Average PT from Brokerages

Shares of Glaukos Co. (NYSE:GKOS) have been given an average rating of “Moderate Buy” by the thirteen ratings firms that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, ten have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among analysts that have covered the stock in the last year is $147.75.

GKOS has been the topic of several research reports. UBS Group initiated coverage on shares of Glaukos in a report on Friday, December 6th. They set a “buy” rating and a $182.00 price target on the stock. Stephens raised Glaukos to a “strong-buy” rating in a report on Monday, December 2nd. Piper Sandler set a $140.00 target price on Glaukos in a research report on Thursday, October 17th. StockNews.com upgraded Glaukos from a “sell” rating to a “hold” rating in a report on Monday, October 21st. Finally, JPMorgan Chase & Co. lifted their target price on shares of Glaukos from $130.00 to $145.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 5th.

Insider Buying and Selling at Glaukos

In other news, Director Gilbert H. Kliman sold 2,000 shares of the business’s stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $144.01, for a total transaction of $288,020.00. Following the completion of the sale, the director now owns 32,336 shares in the company, valued at $4,656,707.36. The trade was a 5.82 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, COO Joseph E. Gilliam sold 2,275 shares of the stock in a transaction on Wednesday, October 30th. The stock was sold at an average price of $138.97, for a total value of $316,156.75. Following the completion of the transaction, the chief operating officer now owns 102,169 shares in the company, valued at approximately $14,198,425.93. This represents a 2.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 17,603 shares of company stock valued at $2,605,678. 6.40% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in GKOS. Wellington Management Group LLP lifted its position in Glaukos by 294.5% in the 3rd quarter. Wellington Management Group LLP now owns 2,183,766 shares of the medical instruments supplier’s stock valued at $284,501,000 after acquiring an additional 1,630,270 shares in the last quarter. State Street Corp lifted its stake in Glaukos by 5.3% during the 3rd quarter. State Street Corp now owns 1,954,449 shares of the medical instruments supplier’s stock valued at $254,626,000 after acquiring an additional 98,109 shares in the last quarter. Fred Alger Management LLC grew its stake in shares of Glaukos by 3.8% in the 2nd quarter. Fred Alger Management LLC now owns 1,278,723 shares of the medical instruments supplier’s stock worth $151,337,000 after acquiring an additional 47,308 shares in the last quarter. Primecap Management Co. CA lifted its position in shares of Glaukos by 2.0% during the third quarter. Primecap Management Co. CA now owns 1,245,185 shares of the medical instruments supplier’s stock valued at $162,223,000 after purchasing an additional 24,370 shares in the last quarter. Finally, Geode Capital Management LLC boosted its holdings in Glaukos by 6.0% during the third quarter. Geode Capital Management LLC now owns 1,172,016 shares of the medical instruments supplier’s stock worth $152,722,000 after purchasing an additional 66,134 shares during the last quarter. 99.04% of the stock is owned by institutional investors.

Glaukos Trading Up 0.9 %

GKOS opened at $161.55 on Friday. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19. Glaukos has a twelve month low of $83.90 and a twelve month high of $163.71. The stock has a market capitalization of $8.91 billion, a price-to-earnings ratio of -53.49 and a beta of 1.04. The company has a 50-day simple moving average of $146.86 and a 200 day simple moving average of $134.31.

Glaukos (NYSE:GKOS) last issued its earnings results on Monday, November 4th. The medical instruments supplier reported ($0.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.20. The firm had revenue of $96.70 million for the quarter, compared to the consensus estimate of $91.50 million. Glaukos had a negative return on equity of 18.99% and a negative net margin of 42.43%. The company’s revenue was up 23.9% compared to the same quarter last year. During the same quarter last year, the business posted ($0.50) EPS. Analysts predict that Glaukos will post -1.89 EPS for the current fiscal year.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.